• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patien

tetano

Editor, Senior Moderator
J Infect Dis. 2019 Jul 17. pii: jiz152. doi: 10.1093/infdis/jiz152. [Epub ahead of print]
[h=1]Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.[/h] Venkatesan S[SUP]1[/SUP], Myles PR[SUP]1[/SUP], Bolton KJ[SUP]2[/SUP], Muthuri SG[SUP]3[/SUP], Al Khuwaitir T[SUP]4[/SUP], Anovadiya AP[SUP]5[/SUP], Azziz-Baumgartner E[SUP]6[/SUP], Bajjou T[SUP]7[/SUP], Bassetti M[SUP]8[/SUP], Beovic B[SUP]9[/SUP], Bertisch B[SUP]10[/SUP], Bonmarin I[SUP]11[/SUP], Booy R[SUP]12[/SUP], Borja-Aburto VH[SUP]13[/SUP], Burgmann H[SUP]14[/SUP], Cao B[SUP]15[/SUP], Carratala J[SUP]16[/SUP], Chinbayar T[SUP]17[/SUP], Cilloniz C[SUP]18[/SUP], Denholm JT[SUP]19[/SUP], Dominguez SR[SUP]20[/SUP], Duarte PAD[SUP]21[/SUP], Dubnov-Raz G[SUP]22[/SUP], Fanella S[SUP]23[/SUP], Gao Z[SUP]24[/SUP], G?rardin P[SUP]25,[/SUP][SUP]26,[/SUP][SUP]27[/SUP], Giannella M[SUP]28,[/SUP][SUP]29[/SUP], Gubbels S[SUP]30[/SUP], Herberg J[SUP]31[/SUP], Higuera Iglesias AL[SUP]32[/SUP], Hoeger PH[SUP]33[/SUP], Hu XY[SUP]34[/SUP], Islam QT[SUP]35[/SUP], Jim?nez MF[SUP]36[/SUP], Keijzers G[SUP]37[/SUP], Khalili H[SUP]38[/SUP], Kusznierz G[SUP]39[/SUP], Kuzman I[SUP]40[/SUP], Langenegger E[SUP]41[/SUP], Lankarani KB[SUP]42[/SUP], Leo YS[SUP]43[/SUP], Libster RP[SUP]44,[/SUP][SUP]45,[/SUP][SUP]46[/SUP], Linko R[SUP]47[/SUP], Madanat F[SUP]48[/SUP], Maltezos E[SUP]49[/SUP], Mamun A[SUP]50[/SUP], Manabe T[SUP]51[/SUP], Metan G[SUP]52[/SUP], Mickiene A[SUP]53[/SUP], Mikić D[SUP]54[/SUP], Mohn KGI[SUP]55,[/SUP][SUP]56[/SUP], Oliva ME[SUP]57[/SUP], Ozkan M[SUP]58[/SUP], Parekh D[SUP]59[/SUP], Paul M[SUP]60[/SUP], Rath BA[SUP]61[/SUP], Refaey S[SUP]62[/SUP], Rodr?guez AH[SUP]63[/SUP], Sertogullarindan B[SUP]64[/SUP], Skręt-Magierło J[SUP]65[/SUP], Somer A[SUP]66[/SUP], Talarek E[SUP]67[/SUP], Tang JW[SUP]68,[/SUP][SUP]69,[/SUP][SUP]70[/SUP], To K[SUP]71[/SUP], Tran D[SUP]72[/SUP], Uyeki TM[SUP]6[/SUP], Vaudry W[SUP]73[/SUP], Vidmar T[SUP]74[/SUP], Zarogoulidis P[SUP]75[/SUP]; PRIDE Consortium Investigators, Nguyen-Van-Tam JS[SUP]1[/SUP].
[h=3]Collaborators (69)[/h]

[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear.
[h=4]METHODS:[/h] We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of <1 day and those who died while hospitalized were excluded.
[h=4]RESULTS:[/h] We analyzed data on 18 309 patients from 70 clinical centers. After adjustment, NAI treatment initiated at hospitalization was associated with a 19% reduction in the LoS among patients with clinically suspected or laboratory-confirmed influenza A(H1N1)pdm09 infection (IRR, 0.81; 95% CI, .78-.85), compared with later or no initiation of NAI treatment. Similar statistically significant associations were seen in all clinical subgroups. NAI treatment (at any time), compared with no NAI treatment, and NAI treatment initiated <2 days after symptom onset, compared with later or no initiation of NAI treatment, showed mixed patterns of association with the LoS.
[h=4]CONCLUSIONS:[/h] When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.


[h=4]KEYWORDS:[/h] IPD meta-analysis; Neuraminidase inhibitors; antivirals; length of stay; pandemic influenza

PMID: 31314899 DOI: 10.1093/infdis/jiz152
 
Back
Top Bottom